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ABSTRACT 
Addiction is a complex process in which behavioral sensitization may be 
an important component. While the behavioral effects of sensitization are well 
established, the intricate neurobiology of the phenomenon is still largely 
unknown. Dopamine systems mediate the induction of behavioral sensitization in 
adult rats, but there is a large amount of evidence showing that other 
neurotransmitter systems also modulate the induction process. For example, the 
α1b-adrenergic and 5-HT2A receptor systems are known to modulate the 
sensitized responding of adult rats, but the roles that these receptor systems play 
in the induction and expression of behavioral sensitization during the preweanling 
period has yet to be investigated. Therefore, the purpose of this thesis was to 
determine whether the serotonergic and adrenergic receptor systems mediate 
the induction and/or expression of cocaine-induced one-trial behavioral 
sensitization in preweanling rats. I used a novel approach to address this 
question, as the receptors of interest were “protected” from the alkylating effects 
of EEDQ (an irreversible nonselective receptor antagonist) by prior treatment 
with selective antagonist drugs. More specifically, rats were given ritanserin (a 
serotonergic receptor antagonist), prazosin (an adrenergic receptor antagonist), 
or a combination of the two drugs prior to an injection of EEDQ. To study the 
induction of behavioral sensitization, this series of injections was administered on 
PD 18 (24 h before the pretreatment injection of cocaine). To study the 
expression of behavioral sensitization, the injections were administered on PD 
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20, which was the day between the drug pretreatment day and the test day. In all 
experiments, the test day (i.e., the day on which the challenge dose of cocaine 
was given) was on PD 21. Control experiments were performed for both the 
induction and expression paradigms in order to determine whether prazosin and 
ritanserin independently affected sensitization. Results showed that the receptor 
inactivation caused by EEDQ blocked both the induction and expression of 
cocaine-induced one-trial behavioral sensitization. Importantly, administering 
prazosin and ritanserin did not protect the induction of the sensitized locomotor 
response, which suggests that serotonergic and adrenergic receptors do not 
mediate cocaine-induced one-trial behavioral sensitization in preweanling rats. 
This conclusion should be tempered, however, because co-administration of 
prazosin and ritanserin affected the locomotor activity and sensitized responding 
of cocaine-treated rats independent of the actions of EEDQ. Considering both 
past and present results, the most harmonious conclusion is that multiple 
receptor systems (i.e., dopaminergic, serotonergic, adrenergic, etc.) work in 
unison to produce the complex phenomenon of behavioral sensitization. 
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CHAPTER ONE 
MODEL OF ADDICTION 
 
 Psychostimulants possess highly addictive qualities and can have 
many complex and detrimental health effects, thus constituting a serious 
public health concern. The acutely rewarding properties of psychostimulants, 
such as cocaine and the amphetamines, often lead to compulsive use 
(Hyman, 1996). In addition, drug users report many adverse effects such as 
anxiety, depression, mood swings, paranoia, and panic attacks, as well as 
sleep and appetite disturbances (Williamson, Gossop, Powis, Griffiths, 
Fountain, & Strang, 1997). 
 Addiction is a complex process in which behavioral sensitization may 
be an important component (Robinson & Berridge, 1993). In animals, 
behavioral sensitization is observed as a progressive increase in behavioral 
responsiveness after repeated treatment with a psychostimulant drug (Kalivas 
& Stewart 1991; Robinson & Becker, 1986). In animal models, sensitization is 
often described in terms of drug-induced changes in locomotor activity or 
stereotyped movement. For example, many studies have reported increased 
locomotor activity after a challenge dose of psychostimulant (Duke, O’Neil, & 
McDougall, 1997; Kalivas & Stewart, 1991; Kolta, Shreve, De Souza, & 
Uretsky, 1985; Leith & Kuczenski, 1982; McDougall, Duke, Bolanos, & 
Crawford, 1994; Robinson & Becker, 1986). In addition, rats given repeated 
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injections of cocaine exhibit increased stereotypy when challenged with a 
high dose of cocaine (Kuczenski & Segal, 1999; Kuczenski, Segal, & 
Aizenstein, 1991; Wood, Tirelli, Snyder, Heyser, LaRocca, & Spear, 1998).  
 Although many studies have used animal models to examine 
psychostimulant-induced behavioral sensitization, the number of studies 
investigating sensitization in humans is limited. The few studies that have 
been done in humans have produced generally positive findings. For 
instance, when participants were given two twice-daily doses of amphetamine 
one day apart, eye-blink rate, energy level, mood, and rate and amount of 
speech increased (Strakowski, Sax, Setters & Keck, 1996). In another study, 
after being given three doses of amphetamine (0.25 mg/kg) at 48 h intervals, 
a progressive increase in eye-blink, mood, energy level, motor activity, and 
speech was observed after each administration of the drug (Sax & 
Strakowski, 1998). Further investigation of this phenomenon lead to the 
finding that mood elevation was affected by characteristics of the participant 
personality, namely neophilia (Sax & Strakowski, 1998; Strakowski, Sax, 
Rosenberg, DelBello, & Adler, 2001). Boileau et al. (2006) concluded that the 
observed increases in mood, as well as changes in underlying neural 
mechanisms, were consistent with the behavioral and neurochemical effects 
occurring in animal sensitization. 
 While the behavioral effects of sensitization are well established, the 
complex neurobiology of the phenomenon is still largely unknown. It has long 
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been recognized that the dopamine system is critically involved in mediating 
reward (Bozarth, 1986). Therefore, it is not surprising that dopaminergic 
pathways are also implicated in the induction of psychostimulant-induced 
behavioral sensitization. This is perhaps best illustrated by studies using 
nonselective or selective dopamine receptor antagonists (Kuribara & 
Uchihashi, 1993; Vezina & Stewart, 1989). Specifically, pretreating rats or 
mice with dopamine antagonists often blocks the induction of 
methamphetamine and cocaine sensitization.  
 Compared to adults, adolescents are more vulnerable to developing a 
drug addiction (Schramm-Sapyta, Walker, Caster, Levin, & Kuhn, 2009; 
Spear, 2000), yet relatively few behavioral sensitization studies have been 
conducted in young rats (for reviews, see Laviola, Adriani, Terranova, & 
Gerra, 1999; Tirelli, Laviola, & Adriani, 2003). In fact, initial reports suggested 
that young rats do not exhibit behavioral sensitization (Fujiwara, Kazahaya, 
Nakashima, Sato, & Otsuki, 1987; Kolta, Scalzo, Ali, & Holson, 1990). Recent 
studies show that behavioral sensitization will occur in young rats, although 
the behavioral sensitization of young rats is often weaker and endures for a 
more limited period of time than in adults (McDougall et al., 1994; Wood et al., 
1998; Zavala, Nazarian, Crawford, & McDougall, 2000). Importantly, these 
differences in the manifestation of behavioral sensitization are specific to the 
multi-trial paradigm. In one-trial sensitization, where testing occurs one or 
more days after a single administration of psychostimulant, the sensitized 
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response is equally robust in young and adult rats (McDougall, Baella, 
Stuebner, Halladay, & Crawford, 2007; McDougall, Cortez, Palmer, Herbert, 
Martinez, Charntikov, & Amodeo, 2009). 
 In addition to ontogenetic differences in the behavioral manifestation of 
sensitization, there is evidence that the underlying neural mechanisms 
responsible for sensitization also change throughout development. For 
example, dopamine D1-like and D2-like receptor stimulation is necessary for 
the induction of one-trial cocaine-induced behavioral sensitization in adult rats 
(Fontana, Post, Weiss, & Pert, 1993; Valjent, Bertran-Gonzalez, Aubier, 
Greengard, Hervé, & Girault, 2010; Weiss, Post, Pert, Woodward, & Murman, 
1989). In contrast, D1-like and D2-like receptor antagonists do not block the 
methamphetamine- or cocaine-induced behavioral sensitization of 
preweanling rats (Mohd-Yusof, Gonzalez, Veliz, & McDougall, 2014; Mohd-
Yusof, Veliz, Rudberg, Stone, Gonzalez, & McDougall, 2016). The latter 
results suggest that the induction of behavioral sensitization in young rats is 
mediated by non-dopaminergic receptor systems. 
 Although dopamine systems are known to mediate the induction of 
behavioral sensitization in adult rats, there is a large amount of evidence 
showing that other neurotransmitter systems also modulate the induction 
process. For example, Auclair, Drouin, Cotecchia, Glowinski, and Tassin 
(2004) reported that blocking α1b-adrenergic and 5-HT2A receptors partially 
attenuated morphine-, cocaine-, and amphetamine-induced behavioral 
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sensitization. Importantly, combined treatment with α1b-adrenergic and 5-
HT2A receptor antagonists fully attenuated the induction of cocaine- and 
amphetamine-induced behavioral sensitization in adult mice (Auclair et al., 
2004).  
 In young rats, the involvement of α1b-adrenergic and 5-HT2A receptor 
systems in the induction of behavioral sensitization had not been investigated. 
Because the dopamine system does not mediate the induction of behavioral 
sensitization in young rats, and antagonists at α1b-adrenergic and 5-HT2A 
receptors attenuate the induction process in adults, I hypothesized that the 
serotonergic and adrenergic systems mediate the induction of behavioral 
sensitization at earlier ages. In summary, the purpose of this thesis was to 
determine whether the serotonergic and adrenergic systems mediate the 
induction of cocaine-induced one-trial behavioral sensitization during the 
preweanling period. The results of this study provide additional knowledge 
about the relationship between neurotransmitter systems underlying 
behavioral sensitization, and increase our understanding of the addiction 
process.   
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CHAPTER TWO 
THE DOPAMINE SYSTEM 
 
Introduction 
 Catecholamines, such as epinephrine, norepinephrine and dopamine, 
are organic compounds that derive from the amino acid tyrosine (Kujar, 
Couceyro, & Lambert, 1999). Of the catecholamines in the central nervous 
system, dopamine is the most abundant. Dopamine is characterized by a 
single amine group, a central molecule of benzene, ethylamine, and hydroxyl 
groups named “catechol” (Feldman, Meyer, & Quenzer, 1997). Reward, 
movement, emotion, and neuroendocrine secretion are a few of the major 
functions regulated by dopamine (Jaber, Robinson, Missale, & Caron, 1996). 
Because of its important role in the function of the central nervous system, 
dopamine dysregulation leads to a number of neuropsychiatric disorders. For 
example, neurodegeneration of the dopamine system can lead to Parkinson’s 
Disease, whereas imbalance and dysfunction within the dopamine system 
plays a role in addiction and schizophrenia.  
 George Barger and James Ewens first synthesized dopamine in 1910 
at Wellcome Laboratories in London, England (Levite, 2012). However, 
dopamine was not discovered to be a neurotransmitter until 1958 by Arvid 
Carlsson and Nils-Ake Hillarp in Sweden (Carlsson, Lindqvist, Magnusson, & 
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Waldeck, 1958). Until this time, dopamine was only thought to be a precursor 
for norepinephrine and epinephrine.  
 
Dopamine Synthesis 
 The initial step in the synthesis of dopamine is the conversion of L-
tyrosine to L-dihydroxyphenylalanine (L-DOPA) in a reaction catalyzed by 
tyrosine hydroxylase (Nagatsu, Levitt, & Udenfriend, 1964). The enzyme 
aromatic amino acid decarboxylase then catalyzes L-DOPA into dopamine 
(Roth, 1979; Sourkes, 1979). The rate limiting step in the production of 
dopamine is the availability of tyrosine hydroxylase, which is regulated by 
multiple feedback mechanisms (Binder, Kinkead, Owens, & Nemeroff, 2001). 
Dopamine production occurs in the presynaptic terminals of dopaminergic 
neurons. Following synthesis, dopamine is packaged into synaptic vesicles 
via a transporter protein generated proton gradient and released via calcium-
dependent exocytosis (Binder et al., 2001). Dopamine can be released either 
tonically or phasically (Keeler, Pretsell, & Robbin, 2014). 
 
Dopaminergic Pathways 
 There are four major pathways that make up the dopaminergic system; 
the nigrostriatal, mesolimbic, mesocortical, and the tuberoinfundibular 
pathways. As the name implies, the nigrostriatal pathway originates in the 
substantia nigra pars compacta, and terminates in the striatum. This pathway 
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is primarily involved in the regulation of motor movement (Geffen, Jessell, 
Cuello, & Iverrson, 1976; Huang, Zhou, Chase, Gusella, Aronin, & DiFiglia, 
1992). The mesolimbic pathway, which is known as the “reward pathway”, 
begins in the ventral tegmental area (VTA) and terminates in the nucleus 
accumbens (Chang & Kitai, 1985). The cell bodies of neurons in the 
mesocortical pathway, which is involved in motivation and emotion, are 
located in the VTA, and the axons project to the prefrontal cortex (Carr & 
Sesack, 2000; Lewis & O’Donell, 2000; Seamans, Floresco, & Phillips, 1998). 
Finally, the tuberoinfundibular pathway projects from the hypothalamus to the 
posterior pituitary. Because of its role in mediating pituitary function, this 
pathway modulates the secretion of hormones (Ben-Jonathan, 1985; Leong, 
Frawley, & Neill, 1983; Sawai, Iijima, Ozawa, & Matsuzaki, 2014). As is 
suggested by the involvement of dopamine in these major pathways, 
dopamine is an important neurotransmitter that is crucial to normal functioning 
of the brain.   
 
Classification of Dopamine Receptors 
 Dopamine receptors are categorized into two families: D1-like 
receptors and D2-like receptors. These families can be further subdivided into 
individual subtypes. Both D1 and D5 receptor subtypes are members of the 
D1-like family, whereas D2, D3, and D4 receptors are part of the D2-like family. 
All dopamine receptors are coupled to G proteins (Keeler et al., 2014). 
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D1-Like Receptors 
 D1-like receptors are generally excitatory (Keeler et al., 2014). These 
receptors are coupled to Gs complexes that, when stimulated, increase the 
activity of adenylyl cyclase. This action, in turn, increases the production of 
cyclic AMP (Kebabian et al., 1984; Roberts-Lewis, Roseboom, Iwaniec, & 
Gnergy, 1986). D1 and D5 receptors have a low affinity for dopamine, causing 
them to be more sensitive to changes in phasic dopamine release (Dreyer, 
Herrik, Berg, & Hounsgaard, 2010; Kebabian et al., 1984).  
 Generally speaking, D1-like receptors are more abundant in brain than 
D2-like receptors (Boyson, McGonigle, & Molinoff, 1986). The D1 subtype 
differs from the D5 subtype in its distribution throughout the brain. In-situ 
hybridization, a technique used to detect gene expression in individual cells, 
shows that D1 receptors are primarily found in the caudate-putamen, nucleus 
accumbens, thalamus, hypothalamus, and olfactory tubercle (Fremeau, 
Duncan, Fornaretto, Dearry, Gingrich, Breese, & Caron, 1991). 
Autoradiography shows that D1 receptors are also found in the substantial 
nigra, as well as the caudate-putamen, nucleus accumbens, and olfactory 
tubercle (Boyson et al., 1986). Ribonuclease protein assays and in-situ 
hybridization suggest that D5 receptors are found in low numbers in the 
hippocampus, cortex, substantia nigra, thalamus, nucleus accumbens and 
caudate-putamen (Choi, Machida, & Ronnekleiv, 1995; Meador-Woodruff, 
Mansour, Grandy, Damask, Civelli, & Watson, 1992). 
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D2-Like Receptors 
 D2-like receptors, in contrast to D1-like receptors, function in an 
inhibitory manner (Keeler, Pretsell, & Robbins, 2014). D2-like receptors are 
coupled with Gi complexes that, when stimulated, inhibit the activation of 
adenylyl cyclase (Kebabian, Beaulieu, & Itoh, 1984; Onali, Schwartz, & Costa, 
1981). In contrast to D1-like receptors, D2-like receptors have a high affinity 
for dopamine, and are more sensitive to changes in tonic dopamine release 
(Dreyer et al., 2010; Kebabian et al., 1984).  
 D2 receptors are distributed widely throughout the brain, but are found 
in lesser densities than D1 receptors (Boyson et al., 1986). Using 
autoradiography, Boyson et al. (1986) found substantial numbers of D2 
receptors in the caudate-putamen, nucleus accumbens, olfactory tubercle, 
substantia nigra, and choroid plexus. In-situ hybridization studies support the 
presence of D2 receptors in the nucleus accumbens, olfactory tubercle, and 
substantia nigra, as well as the ventral tegmental area (Meador-Woodruff, 
Mansour, Bunzow, Van Tol, Watson, & Civelli, 1989).  
 D3 receptors are not as widely distributed as D2 receptors. In a study 
employing both autoradiography and in-situ hybridization, D3 receptors were 
expressed abundantly in the islands of Calleja, but were expressed more 
restrictedly in the nucleus accumbens, substantia nigra, ventral tegmental 
area, and cerebellum (Diaz, Lévesque, Lammers, Griffon, Martres, Schwartz, 
& Sokoloff, 1995). Finally, while D2 and D3 receptors are primarily expressed 
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in the basal ganglia, D4 receptors are mainly found in the entorhinal cortex, 
lateral septal nucleus, hippocampus, and the medial preoptic area of the 
hypothalamus (Primus, Thurkauf, Xu, Yevich, McInerney, Shaw, Tallman, & 
Gallager, 1997). 
 
Ontogeny of the Dopamine System 
 It is well established that the dopamine system changes throughout 
ontogeny. Interestingly, D1-like and D2-like receptors develop on different 
schedules. Specifically, D1-like receptors are most abundant at postnatal day 
(PD) 40, whereas, D2-like receptor numbers peak between PD 25 and 40 
(Teicher, Andersen, & Hostetter, 1995). After these time points, the receptors 
are pruned to adult levels (Teicher et al., 1995). In addition, the rate of 
proliferation of D1-like and D2-like receptors varies across ontogeny. 
Although rats are born with an approximately equal number of each receptor 
type, there are three times as many D1-like receptors than D2-like receptors 
when rats reach adulthood (Gelbard, Teicher, Faedda, & Baldessarini, 1989). 
 The concentration of dopamine in the central nervous system also 
changes across early development. Specifically, dopamine levels in rat brain 
increase steadily until adulthood (Agrawal, Glisson, & Himwich, 1966). In 
addition, the daily cyclicity of brain dopamine levels differs according to age. 
For example, radioenzymatic assays show that dopamine concentrations in 3- 
and 21-day-old rabbits peak during the early light phase; whereas, the 
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dopamine concentrations of adult animals peak during the early dark phase 
(Gingras, Lawson, & McNamara, 1995). Further, different brainstem regions 
develop unique patterns of dopamine cyclicity that change across ontogeny 
(Gingras et al., 1995).  
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CHAPTER THREE 
SEROTONIN AND NOREPINEPHRINE PHARMACOLOGY 
 
Introduction: Serotonin 
 The monoamine neurotransmitter 5-hydroxytryptamine (5-HT), more 
commonly referred to as serotonin, is found diffusely across the central 
nervous system. Serotonin has a role in many cognitive processes, such as 
anxiety, memory, and aggression (Bear, Connors, & Paradiso, 2007). In 
addition, serotonin modulates the release of many other neurotransmitters, 
such as glutamate, GABA, epinephrine, norepinephrine, and dopamine 
(Ciranna, 2006). The modulatory action of serotonin is also important for the 
control of motor movement, as serotonin receptor antagonists attenuate 
hyperlocomotion and stereotypy (Carlsson, Martin, Nilsson, Sorenson, 
Carlsson, Waters, & Waters, 1999; Higgins, Enderlin, Haman, & Fletcher, 
2003). Because of the varied roles of serotonin, it is no surprise that 
serotonergic dysfunction is implicated in several diseases, such as major 
depression, Alzheimer’s Disease, and schizophrenia (Ciranna, 2006). 
 
Serotonin Synthesis 
 Serotonin is synthesized in the central nervous system in two steps. 
First, tryptophan is hydroxylated by tryptophan hydroxylase (TPH) to form 5-
hydroxytryptophan (5-HTP). Second, 5-HTP is decarboxylated by aromatic L-
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amino acid decarboxylase (AADC) to create serotonin (Fitzpatrick, 1999; Li, 
Chalazonitis, Huang, Mann, Margolis, Yang, Kim, Côté, Mallet, & Gershon, 
2011). This process primarily occurs in the raphe, where the majority of 
serotonergic cell bodies are located (Abrams, Johnson, Hollis, & Lowry, 
2004).  
 The location of serotonergic cell clusters has largely been studied with 
immunocytochemical localization, and can be grouped into three pathways 
(Cooper, Bloom & Roth, 2003). The serotonergic cell bodies located more 
caudally project to the medulla and spinal cord, whereas the cell bodies 
located more rostrally project to the telencephalon and diencephalon. Finally, 
the clusters located in intermediate areas primarily innervate the cortex 
(Cooper et al., 2003).  
 
Classification of Serotonin Receptors 
 Serotonin receptors are generally categorized into seven distinct 
families. The families, 5-HT1-7, include subtypes that differ slightly in structure 
and function (for reviews, see Barnes & Sharp, 1999; Bradley, Engel, Feniuk, 
Fozard, Humphrey, Middlemiss, Mylecharane, Richardson, & Saxena, 1986; 
Glennon, 2003; Hoyer, Hannon, & Martin, 2002; Tecott & Julius, 1993). With 
the exception of 5-HT3, which is ligand gated, most of the serotonin receptor 
types are coupled to G proteins (Ciranna, 2006). Typically, serotonin 
receptors are studied using radioligand binding assays, autoradiographic 
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mapping, and, more recently, in-situ hybridization (Hoyer et al., 2002). Using 
in-situ hybridization, Sumner, Rosie, and Fink (1992) reported that 5-HT1a 
mRNA was found in the suprachiasmatic nucleus, supraoptic nucleus, 
paraventricular nucleus, medial septum, medial preoptic area, ventromedial 
hypothalamic nucleus, and perikarya of the diagonal band of Broca, as well 
as the hippocampus. Autoradiographic analysis revealed that 5-HT1a binding 
sites were highly concentrated in the dentate gyrus, hippocampus, lateral 
septum, and frontal cortex, whereas 5-HT1b binding sites were highly 
concentrated in the caudate nucleus, globus pallidus, and substantia nigra 
(Vergé, Daval, Marcinkiewicz, Patey, el Mestikawy, Gozian, & Hamon, 1986). 
5-HT1c mRNA, on the other hand, was found in the dorsal and median raphe 
nuclei, as well as the lateral septum and choroid plexus (Sumner et al., 1992).  
 Not surprisingly, in-situ hybridization and autoradiography have 
revealed that 5-HT2 and 5-HT3 receptors are found in similar locations as the 
5-HT1 family. For example, 5-HT2 mRNA was found in the cingulate and 
frontal cortices, medial septum, medial preoptic area, ventromedial 
hypothalamic nucleus, perikarya of the diagonal band of Broca, and dorsal 
and median raphe nuclei (Sumner et al., 1992). In addition, autoradiographic 
analysis revealed a high density of 5-HT2 receptor binding sites in the cortex 
and the caudate putamen (Schotte & Leysen, 1988). Further, calcium binding 
has shown that 5-HT3 mRNA is located in the neocortex, olfactory cortex, 
hippocampus, and amygdala (Morales & Bloom, 1997). Using 
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autoradiography, high densities of 5-HT3 receptor binding sites were also 
found in the amygdala, hippocampus, frontal cortex, and entorhinal cortex 
(Laporte, Koscielniak, Ponchant, Vergé, Hamon, & Gozlan, 1992).  
 
Ontogeny of the Serotonin System 
 In rats, 5-HT neurotransmitter levels peak at PD 5, and then decline 
until PD 7 (Artigas, Suñol, Tussel, Martínez, & Gelpí, 1985; Bennett & 
Giarman, 1965; Nachmias, 1960). Following PD 7, 5-HT levels increase 
gradually until they reach adult levels at about PD 15 (Artigas et al., 1985). 
Importantly, the density of serotonergic receptors changes across ontogeny. 
In rats, the density of 5-HT1 receptors increases after birth, with adult levels 
being reached around PD 9 to PD 14 (Zilles, Schleicher, Glaser, Traber, & 
Rath, 1985). In contrast, 5-HT2 receptor densities increase rapidly during the 
first postnatal week, until asymptoting at PD 7 (Morilak & Ciaranello, 1993). At 
PD 28, 5-HT2 receptor levels then decline to adult levels (Morilak & 
Ciaranello, 1993).  
 
Introduction: Norepinephrine 
 Norepinephrine, like dopamine, is a catecholamine neurotransmitter 
that derives from tyrosine (Kujar et al., 1999). Norepinephrine was first 
discovered in 1946 by Ulf von Euler, and further investigated by Peter Holtz in 
1957 (Shore & Olin, 1958). In general, norepinephrine is important for the 
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“fight or flight” response, but it is also critical for attention, cognition, learning, 
memory, stress, and mood regulation (Aston-Jones, Rajkowski, & Cohen, 
1999; Ordway, Schwartz & Frazer, 2012). Because norepinephrine is 
necessary for many basic brain functions, it is not a surprise that dysfunction 
involving this system can lead to disorders such as major depression, anxiety, 
and schizophrenia (Anand & Charney, 2000; Biederman & Spencer, 1999; 
Goldstein, 1981; Redmond & Huang, 1979). 
 
Norepinephrine Synthesis 
 Norepinephrine is a catecholamine that derives from phenylalanine. 
First, tyrosine hydroxylase converts tyrosine into L-DOPA. Second, L-DOPA 
is catalyzed by aromatic amino acid decarboxylase, resulting in dopamine 
(Roth, 1979; Sourkes, 1979). Finally, dopamine is transported into vesicles 
where it is converted by the enzyme dopamine β-hydroxylase into 
norepinephrine (Kaufman, 1974; Kujar et al., 1999). Cell bodies of 
noradrenergic neurons are primarily located in the pons, especially in the 
locus coeruleus (Samuels & Szabadi, 2008). From the locus coeruleus, 
noradrenergic projections form two major pathways (Noback, Strominger, 
Demarest, & Ruggiero, 2005). First, axons comprising the central tegmental 
tract project to the hypothalamus (Nurcombe & Gallagher, 1986). Second, the 
dorsal longitudinal fasciculus innervates the medulla, cortex, thalamus, and 
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hippocampus (Nurcombe et al., 1986). Rostrally, these pathways converge in 
the medial forebrain bundle (Segal, Yager, & Sullivan, 1976).  
 
Classification of Norepinephrine Receptors 
 There are two families of adrenergic receptors, alpha and beta 
(Ordway et al., 2012). Adrenergic receptors from both families are coupled to 
G proteins (Qin, Sethi, & Lambert, 2008). The alpha family has two subtypes 
(α1 and α2), and the beta family has three subtypes (β1, β2, and β3). Recently, 
the α1 and α2 subtypes have each been further classified into three groups 
(α1a, α1b, and α1d; α2a, α2b, and α2c) (Taniguchi, Ukai, Tanaka, Yano, Kimura, 
Moriyama, & Kawabe, 1997). In-situ hybridization studies show that mRNA of 
the α1a group was found mainly in the globus pallidus, olfactory bulb, and 
spinal cord (Chapple, Burt, Andersson, Greengrass, Wyllie, & Marshall, 
1994), whereas α1b and α1d mRNA is located mainly in the cortex (Weinberg, 
Trivedi, Tan, Mitra, Perkins-Barrow, Borkowski, Strader, & Bayne, 1994). In 
contrast, receptors from the α2 groups are more widely dispersed in the brain. 
For example, in-situ hybridization studies show that α2a mRNA is located in 
the cortex, locus coeruleus, reticular formation, pontine nuclei, thoracic spinal 
cord, and the paraventricular nucleus of the hypothalamus (Dalman & Neubig, 
1991; Nicholas, Pieribone, & Hökfelt, 1993). In the central nervous system, a 
small amount of α2b-receptor mRNA is found in the hypothalamus; whereas, 
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α2c-receptor mRNA is located in the olfactory bulb, cortex, striatum, dorsal 
root ganglion, and hippocampus (Nicholas et al., 1993). 
 The second family of norepinephrine receptors, the β-adrenergic, has 
three subtypes. The α1 subtype is not found in the central nervous system, but 
rather in cardiac and stomach tissue (Zhao, Sakata, Li, Liang, Richardson, 
Brown, Goldstein, & Zigman, 2010). This is also the case for the β3 subtype, 
which is found in the colon, gall bladder, and adipose tissue (Krief, Lönnqvist, 
Raimbault, Baude, Van Spronsen, Arner, Strosberg, Ricquier, & Emorine, 
1993). In contrast, β2-receptors are located in the amygdala, cerebellum, and 
cortex, as well as the heart, smooth muscle, liver, and kidneys (Beane & 
Marrocco, 2004; Elenkov, Wilder, Chrousos, & Vizi, 2000). 
 
Ontogeny of the Norepinephrine System 
 The levels of norepinephrine in the developing rat brain follow a similar 
pattern as the levels of serotonin. Norepinephrine neurotransmitter levels 
increase dramatically from PD 1 to PD 2 (Dygalo, Iushkova, Kalinina, Surnina, 
Mel’nikova, & Shishkina, 2000). After the initial peak, there is a decline until 
PD 5, after which there is a gradual increase until PD 30 when adult levels 
are reached (Dygalo et al., 2000; Karki, Kuntzman, & Brodie, 1962).  
 In terms of receptor densities, β-adrenergic receptors sharply increase 
in density soon after birth, and at three weeks achieve adult levels (Dygalo et 
al., 2000). In contrast, adult-like levels of α2-receptors are already present at 
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PD 1 (Happe, Coulter, Gerety, Sanders, O’Rourke, Bylund & Murrin, 2004). 
Interestingly, the density of α1-receptors depends on neuroanatomical 
location. For example, α1-receptors in the globus pallidus increase in density 
from PD 1 to PD 7, and then undergo pruning throughout the remainder of 
life. In the olfactory bulb, α1-receptors increase in number for the first two 
weeks after birth and then remain at a constant level thereafter (Jones, 
Gauger, Davis, Slotkin & Bartolome, 1985). 
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CHAPTER FOUR 
ADULT BEHAVIORAL SENSITIZATION 
 
Indirect Dopamine Agonists: Adult Multi-Trial  
Behavioral Sensitization 
 Typically, multi-trial behavioral sensitization consists of 4-6 daily 
injections of an indirect dopamine agonist, followed by a withdrawal period, 
and then the administration of a challenge injection of the same agonist 
(Robinson & Becker, 1986). Sensitization is characterized by a heightened 
behavioral response following the challenge injection. Enhanced locomotor 
activity is the most commonly studied sensitized response in rats, although 
intense stereotypy can also occur. A multiphasic behavioral response is also 
possible. For example, repeatedly administering a high dose of amphetamine 
causes an initial increase in locomotor activity followed by intense stereotypy, 
and then a period of post-stereotypy locomotion (Leith & Kuczenski, 1982). 
These components of the sensitized response persist for different periods of 
time, with stereotypy lasting longer than locomotor activity (Leith & Kuczenski, 
1982). 
 Although the persistance of sensitized stereotypy and locomotor 
activity differ, the intensity of each response is similarly affected by drug dose. 
Specifically, larger doses of a psychostimulant will produce more robust 
sensitized stereotypy and locomotor activity (Frantz, O’Dell, & Parsons, 2007; 
Post & Rose, 1976). For example, five administrations of a small dose (10 
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mg/kg) of cocaine lead to increased locomotion and stereotypy, whereas six 
administrations of a large dose (40 mg/kg) of cocaine generated more intense 
locomotion and stereotypy (Davidson, Lazarus, Lee, & Ellinwood, 2002; 
Frantz et al., 2007). Even at smaller doses of amphetamine (0.5, 1.0, or 1.5 
mg/kg), a gradual strengthening of the sensitized response occurs as the 
drug dose increases (Hooks, Jones, Neill, & Justice, 1992). In sum, it is clear 
that in multi-trial behavioral sensitization the psychostimulant dose is 
positively correlated with the intensity of the sensitized response.  
 Importantly, the multi-trial procedure produces a sensitized locomotor 
response that persists for a long period of time in adult rats. In fact, behavioral 
sensitization can be observed for many months after drug administration is 
discontinued (Kalivas & Stewart, 1991; Kolta et al., 1985; Leith & Kuczenski, 
1982; Robinson & Becker, 1986). In general, the robustness of the sensitized 
response to cocaine and amphetamine increases as the period of withdrawal 
increases (Heidbreder, Thompson, & Shippenberg, 1996; Kalivas & Duffy, 
1993a, 1993b; Kolta et al., 1985; Segal & Kuczenski, 1992; Vanderschuren, 
Schmidt, De Vries, Van Moorsel, Tilders, & Schoffelmeer, 1999). Behavioral 
sensitization observed within a week of drug discontinuation is considered 
short-term sensitization, whereas a sensitized response observed weeks to 
months later is considered long-term sensitization. This distinction is 
important, since the neural mechanisms mediating short- and long-term 
behavioral sensitization differ. In fact, the neuroadaptations responsible for 
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short-term behavioral sensitization disappear over time, yet are a necessary 
precursor for neuroadaptations that support long-term sensitization (for 
reviews, see Pierce & Kalivas, 1997; White, Hu, Zhang, & Wolf, 1995; White 
& Kalivas, 1998; Wolf, 1998). 
  The robustness of the sensitized response can also be affected by the 
context in which the drug is administered. It is evident that a stronger 
sensitized response occurs when drug pretreatment and testing occur in the 
same environment (Anagnostaras & Robinson, 1996). Context independent 
sensitization is possible, but only when higher doses of cocaine are 
repeatedly administered to adult rats or mice (Badiani, Browman, & Robinson, 
1995; Browman, Badiani, & Robinson, 1998; Crombag, Badiani, Chan, 
Dell’Orco, Dineen, & Robinson, 2001). Similarly, multi-trial amphetamine 
sensitization is more robust when the drug is administered in a previously 
novel environment (Crombag, Badiani, Maren, & Robinson, 2000). In addition, 
drug-environment associations are important for the persistence of the 
sensitized response (Anagnostaras & Robinson, 1996). Together, these 
results show that associative learning is an important part of the sensitization 
process in adult rats and mice. 
 Pavlovian conditioning is the primary associative process involved in 
behavioral sensitization. Specifically, the environmental context acts as the 
conditioned stimulus (CS), and the psychostimulant is the unconditioned 
stimulus (US). After repeated drug-environment pairings, the CS elicits a 
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potentiated locomotor response (i.e., a conditioned response, CR) if the 
animal is tested in the same environmental context (Franklin & Druhan, 2000; 
Johnson, Sediqzadah, & Erb, 2012; Michel & Tirelli, 2002). According to 
classical learning theory, the robustness of the CR should increase with the 
number of CS-US pairings (Mackintosh, 1974). Consistent with this tenet, 
Michel, Tambour, and Tirelli (2003) found that rats injected with cocaine for 
12 days, as opposed to 3 or 6 days, exhibited a more robust sensitized 
response on the test day. As will be discussed shortly, Pavlovian contextual 
conditioning appears to be even more essential for the one-trial behavioral 
sensitization of adult rats and mice (Battisti, Chang, Uretsky, & Wallace, 
1999; Jackson & Nutt, 1993; Weiss et al., 1989).  
   
Indirect Dopamine Agonists: Adult One-Trial  
Behavioral Sensitization 
 Research regarding multi-trial behavioral sensitization in adults is 
extensive; however, studies examining one-trial behavioral sensitization are 
more limited. One-trial behavioral sensitization consists of two administrations 
of the same drug (i.e., a pretreatment dose and a challenge dose). This 
procedure is also known as a two-injection protocol of sensitization (TIPS; 
Valjent et al., 2010). Relative to the multi-trial procedure, the one-trial 
paradigm has some distinct advantages because it minimizes the possibility 
of dopamine receptor up-regulation and dopamine supersensitivity due to 
multiple agonist administrations (Mohd-Yusof et al., 2016; Robinson & 
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Becker, 1986; Valjent et al., 2010; White, Joshi, Koeltzow, & Hu, 1998). The 
one-trial paradigm also provides an unbiased procedure for differentiating the 
induction and expression of behavioral sensitization (Valjent et al., 2010). 
 As with multi-trial behavioral sensitization, the one-trial procedure can 
result in a sensitized locomotor or stereotypic response. With high doses of 
amphetamine, intense stereotyped behaviors occur after a single conditioning 
trial (Battisti et al., 1999). In contrast, locomotor sensitization is evident when 
adult mice are pretreated with a single moderate dose of cocaine or morphine 
(Valjent et al., 2010). The one-trial behavioral sensitization of adult rats and 
mice shows great persistence, as a sensitized locomotor response is still 
detectable months after a single psychostimulant administration (Fontana et 
al., 1993; Robinson, Becker, & Presty, 1982; Valjent et al., 2010).  
 Although there is only one conditioning trial, associative learning is 
necessary for the induction of one-trial behavioral sensitization in adult 
animals (for a discussion, see White et al., 1998). While the induction of multi-
trial behavioral sensitization is strengthened by contextual conditioning, the 
one-trial behavioral sensitization of adult rats and mice is completely context 
dependent (Battisti et al., 1999; Jackson & Nutt, 1993; Weiss et al., 1989). 
Several different methodologies have been employed to investigate whether 
context-independent one-trial sensitization is obtainable, but all attempts thus 
far have failed (Battisti et al., 1999; Weiss et al., 1989). For example, Battisti 
et al. (1999) administered amphetamine or apomorphine to adult mice and 
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then placed them in various environments (cages of different size, color, etc.). 
When mice were tested in a distinctly different environment, there was no 
evidence of a sensitized response. Context dependency can also be shown 
when rats are pretreated with a psychostimulant in their home cage and then 
tested in a novel environment (Badiani et al., 1995; Post, Lockfeld, Squillace, 
& Contel, 1981). In addition, drug dose is an important constraint for one-trial 
behavioral sensitization, because increasing the dose of the agonist 
increases the intensity of the sensitized response (Battisti et al., 1999). This 
finding is consistent with Pavlovian principles, as enhancing CS intensity (i.e. 
the drug dose) should increase the robustness of the CR (i.e. the locomotor 
response).   
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CHAPTER FIVE 
ADULT BEHAVIORAL SENSITIZATION:  
NEURAL MECHANISMS 
 
 Studies regarding the neural mechanisms underlying multi-trial 
behavioral sensitization in adult rats primarily focus on dopaminergic systems, 
although recent studies have also examined serotonergic and noradrenergic 
mediation. Interestingly, the neural mechanisms underlying behavioral 
sensitization differ depending on the type of psychostimulant used. For 
example, glutamatergic mechanisms involved in cocaine sensitization appear 
to be unimportant for amphetamine sensitization (for a review, see 
Vanderschuren & Kalivas, 2000).  
 
Dopamine Receptor Systems Underlying  
Behavioral Sensitization 
Multi-Trial Behavioral Sensitization  
 Perhaps not surprisingly, the dopamine receptor subtypes mediating 
the induction and expression of behavioral sensitization differ according to 
both the induction paradigm employed (one- vs. multi-trial) and the 
psychostimulant used. For example, neither D1-like nor D2-like receptor 
antagonists block the induction of multi-trial cocaine sensitization in adult rats 
(Mattingly, Hart, Lim & Perkins, 1994). In contrast, both D1-like and D2-like 
receptor antagonists block the induction of multi-trial amphetamine and 
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methamphetamine sensitization (Kelly, Low, Rubinstein & Phillips, 2008; 
Kuribara & Uchihashi, 1993, 1994; White et al., 1998). Dopamine receptors 
play a different role in the expression of multi-trial behavioral sensitization. 
More specifically, the expression of multi-trial cocaine sensitization is 
prevented when D1-like receptor antagonists are administered before cocaine 
on the test day (Sorg, Li, & Wu, 2001; White et al., 1998). In contrast, D1-like 
and D2-like receptor antagonists do not block the expression of 
amphetamine-induced multi-trial behavioral sensitization in adult rats (Moro, 
Sato, Ida, Oshima, Sakurai, Shihara, Horikawa, & Mukini, 2007).  
One-Trial Behavioral Sensitization 
 Unlike multi-trial behavioral sensitization, a functioning dopamine 
system is necessary for the induction of one-trial cocaine sensitization in adult 
rats. It has been reported in more than one study that D1-like and D2-like 
receptor antagonists block the induction of one-trial cocaine sensitization in 
adult rats (Fontana et al., 1993; Weiss et al., 1989; see also Valjent et al., 
2010). Interestingly, expression of one-trial cocaine sensitization is not 
affected by dopamine receptor antagonism, since administering D1-like and 
D2-like receptor antagonists before cocaine treatment on the test day does 
not prevent the occurrence of a sensitized response (Fontana et al., 1993). 
No studies have examined the effects of selective dopamine receptor 
antagonists on the induction and expression of one-trial amphetamine and 
methamphetamine behavioral sensitization.  
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 In summary, a number of interesting yet inconsistent findings have 
been reported concerning cocaine sensitization: first, neither D1-like nor D2-
like receptor antagonists block the induction of multi-trial behavioral 
sensitization; second, both D1-like and D2-like receptor antagonists block the 
induction of one-trial behavioral sensitization; third, only D1-like receptor 
antagonists block the expression of multi-trial behavioral sensitization; and 
fourth, neither D1-like nor D2-like receptor antagonists block the expression 
of one-trial behavioral sensitization. 
 
Serotonin and Adrenergic Receptor Systems  
Underlying Behavioral Sensitization 
 The inconsistent actions of D1-like and D2-like receptor antagonists on 
the induction and expression of cocaine sensitization strongly suggest that 
some other receptor system is more fundamentally involved in mediating the 
neural processes underlying behavioral sensitization. Because cocaine 
increases synaptic levels of both dopamine and serotonin (for reviews, see 
Meyer & Quenzer, 2005; Vanderschuren & Kalivas, 2000), White et al. (1998) 
proposed that redundant dopamine and serotonin pathways may mediate the 
induction of cocaine sensitization. In fact, recent evidence suggests that the 
serotonergic system, as well as the noradrenergic system, are important 
mediators of behavioral sensitization. 
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Serotonin Receptor Systems: Multi-Trial Behavioral Sensitization  
 In terms of the serotonin system, the involvement of specific receptor 
subtypes in behavioral sensitization appears to depend on the 
psychostimulant used. For example, 5-HT2C receptor antagonists block the 
induction of multi-trial cocaine sensitization (Craige & Unterwald, 2013); 
whereas, the induction of multi-trial methamphetamine sensitization is 
blocked by a 5-HT3 receptor antagonist (Yoo, Nam, Lee, & Jang, 2006). The 
serotonergic receptors mediating the induction of multi-trial behavioral 
sensitization are often the same as those mediating expression. For instance, 
5-HT2 and 5-HT3 receptor antagonists block the expression of multi-trial 
cocaine sensitization in adult rats (Davidson, Lazarus, Xiong, Lee, & 
Ellinwood, 2002; King, Xiong, Douglas, & Ellinwood, 2000; King, Xiong, & 
Ellinwood, 1998). In addition, the expression of methamphetamine-induced 
multi-trial behavioral sensitization is prevented by the non-selective 5-HT2 
receptor antagonist ritanserin (Ago, Nakamura, Baba, & Matsuda, 2007). 
Serotonin Receptor Systems: One-Trial Behavioral Sensitization 
 The serotonergic receptors necessary for multi-trial behavioral 
sensitization are also important for one-trial sensitization. For example, 
administering 5-HT3, 5-HT2A, and 5-HT2C receptor antagonists prior to 
methamphetamine on the pretreatment day blocks the induction of one-trial 
behavioral sensitization (Steed, Jones, & McCreary, 2011; Yoo, Nam, Lee, & 
Jang, 2008). The induction of amphetamine and cocaine one-trial behavioral 
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sensitization is also prevented by 5-HT2 receptor antagonism (O’Neill, Heron-
Maxwell, & Shaw, 1999). Unfortunately, no studies have examined the effects 
of selective serotonin antagonists on the expression of one-trial cocaine and 
methamphetamine sensitization. In summary, it is clear that the 5-HT2 and 5-
HT3 receptor families are important for the induction of multi- and one-trial 
behavioral sensitization of adult animals, but their role in expression is 
uncertain. 
Adrenergic Receptor Systems: Multi-Trial Behavioral Sensitization 
 Studies examining the role of adrenergic receptor systems in 
behavioral sensitization are less abundant than those assessing serotonin 
and dopamine system involvement. In a comprehensive study, Auclair et al. 
(2004) found that concomitant administration of 5-HT2 and α1-adrenergic 
receptor antagonists inhibits the induction and expression of multi-trial 
behavioral sensitization to both amphetamine and cocaine (Auclair et al., 
2004; see also Drouin, Blanc, Villégier, Glowinski, & Tassin, 2002). 
Consistent with these findings, amphetamine- and cocaine-induced locomotor 
activity is dramatically attenuated in mice lacking α1-adrenergic receptors 
(Drouin et al., 2002). The locus of these effects may be the nucleus 
accumbens, since infusing an α1-adrenergic antagonist into the accumbens 
prevents the induction of amphetamine-induced behavioral sensitization 
(Blanc, Trovero, Vezina, Hervé, Godeheu, Glowinski, & Tassin, 1994). 
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Adrenergic Receptor Systems: One-Trial Behavioral Sensitization 
 Studies investigating the involvement of the adrenergic receptor 
system in one-trial behavioral sensitization are limited. Both α2-adrenergic 
and α1-adrenergic antagonists block the induction of amphetamine 
sensitization, but not cocaine sensitization (Vanderschuren, Beemster, & 
Schoffelmeer, 2003). As mentioned above, concurrent blockade of 5-HT2 and 
α1-adrenergic receptors prevents the induction of one-trial cocaine and 
amphetamine sensitization (Auclair et al., 2004). No studies have examined 
the effects of selective adrenergic antagonists on the expression of one-trial 
behavioral sensitization in adult rats. 
 In summary, receptor antagonist and knock-out studies provide strong 
evidence that serotonin and norepinephrine receptor systems mediate at least 
some components of behavioral sensitization. First, 5-HT2 receptor 
antagonists block the induction of one- and multi-trial cocaine sensitization; 
second, 5-HT3 receptor antagonists prevent the induction of one-trial 
methamphetamine sensitization; third, co-administration of 5-HT2 and α1-
adrenergic receptor antagonists completely prevents the induction and 
expression of cocaine and methamphetamine multi-trial sensitization; and, 
fourth, “knocking out” α1-adrenergic receptors attenuates psychostimulant-
induced locomotor activity. Collectively, the available evidence suggests that 
the serotonergic and noradrenergic systems are critically involved in the 
mediation of behavioral sensitization in adult rats and mice.  
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CHAPTER SIX 
PREWEANLING BEHAVIORAL SENSITIZATION 
 
Indirect Dopamine Agonists: Preweanling  
Multi-Trial Behavioral Sensitization 
 As is true of adult rats, psychostimulant-induced behavioral 
sensitization occurs in young rats (Duke et al., 1997; McDougall et al., 1994; 
Wood et al., 1998). Importantly, the manifestation of behavioral sensitization 
is different in young rats, as the sensitized response in younger animals is 
much less robust than in adults (Smith & Morrell, 2008). Additionally, the 
sensitization of adult rats persists for months after cessation of drug 
administration (Kalivas & Stewart, 1991; Leith & Kuczenski, 1982; Robinson & 
Becker, 1986); whereas, the sensitized response of young rats only lasts for a 
week or two after cessation of drug administration (McDougall et al., 1994; 
Wood et al., 1998; Zavala et al., 2000). The latter finding suggests that the 
neural mechanisms involved in long-term behavioral sensitization are not yet 
mature in young rats. As for short-term behavioral sensitization, the 
mechanisms underlying induction and expression are functional by at least 
PD 10 (Tirelli, 2001).  
 As with adult rats, associative learning modifies the multi-trial 
behavioral sensitization of preweanling rats. For example, repeatedly 
administering cocaine in a novel environment causes a sensitized stereotypic 
response in young rats; whereas, administering the drug in the home cage 
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produces no sensitization (Wood et al., 1998). After 10 daily injections of 
cocaine and a short abstinence period (i.e. one day) context-independent 
behavioral sensitization occurs, although after a long abstinence period (i.e. 
one week) behavioral sensitization is context-dependent (Zavala et al., 2000). 
In addition, after only three pretreatment injections of cocaine and a 24 h 
withdrawal period, context-independent behavioral sensitization occurs in 
preweanling rats (McDougall et al., 2009). In agreement with classical 
learning theory, the longevity of the sensitized response increases as the 
number of pretreatment psychostimulant administrations increases (Zavala et 
al., 2000). In other words, increasing the number of CS-US pairings enhances 
the persistence of the CR. 
 
Indirect Dopamine Agonists: Preweanling  
One-Trial Behavioral Sensitization 
 Preweanling rats show robust one-trial psychostimulant-induced 
behavioral sensitization (McDougall et al., 2007; McDougall, Kozanian, 
Greenfield, Horn, Gutierrez, Mohd-Yusof, & Castellanos, 2011). The 
sensitized response is strongest when testing occurs one to three days after 
drug pretreatment and disappears entirely after five days (McDougall et al., 
2009). Interestingly, the different classes of dopamine agonists preferentially 
induce behavioral sensitization at different ontogenetic ages (Kozanian, 
Gutierrez, Mohd-Yusof, & McDougall, 2012; McDougall, Nuqui, Quiroz, & 
Martinez, 2013; McDougall et al., 2011). For example, one-trial amphetamine- 
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and methamphetamine-induced behavioral sensitization was observed in rats 
tested on postnatal day (PD) 13 and PD 17 (McDougall et al., 2011, 2013); 
whereas, cocaine  preferentially induces behavioral sensitization at PD 21 
(Kozanian et al., 2012). These data suggest that each drug activates the 
neural mechanisms underlying behavioral sensitization in slightly different 
ways.   
 Interestingly, the relative importance of contextual stimuli is the most 
striking age-dependent difference in the ontogeny of behavioral sensitization. 
In adult rats, contextual conditioning is necessary for robust one-trial 
behavioral sensitization (Battisti, Uretsky, & Wallace, 2000; Jackson & Nutt, 
1993; Weiss et al., 1989). In contrast, preweanling rats show strong context-
independent behavioral sensitization with the one-trial paradigm (Herbert, 
Der-Ghazarian, Palmer, & McDougall, 2010; McDougall et al., 2009). For 
example, preweanling rats pretreated with cocaine in the home cage or in a 
novel chamber show no difference in sensitized responding when tested in an 
activity chamber (Herbert et al., 2010). Furthermore, young rats anesthetized 
before receiving a pretreatment injection of cocaine still show a sensitized 
response on the test day (Herbert et al., 2010). Finally, electroconvulsive 
shock-induced retrograde amnesia administered a few h after a pretreatment 
dose of cocaine does not prevent the expression of a sensitized response 
(McDougall et al., 2011). These various results show that associative learning 
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processes are not necessary for the one-trial behavioral sensitization of 
preweanling rats. 
 Overall, it is clear that behavioral sensitization is manifested differently 
in preweanling and adult rats. Adult behavioral sensitization is more robust 
than in preweanling rats (Smith & Morrell, 2008). In addition, the effects of 
contextual conditioning are stronger in adults than pups, an effect that is 
especially evident in the one-trial paradigm (Battisti et al., 2000; Herbert et al., 
2010; Jackson & Nutt, 1993; McDougall et al., 2009; Weiss et al., 1989). 
Finally, the behavioral sensitization exhibited by adult rats shows much 
greater persistence than in younger rats (Kalivas & Stewart, 1991; Kolta et al., 
1985; Leith & Kuczenski, 1982; Robinson & Becker, 1986; Zavala et al., 
2000). Taken together, the implications of these data are two-fold. First, the 
neural mechanisms underlying behavioral sensitization appear to differ in 
preweanling and adult rats. For example, young rats possess the non-
associative neural mechanisms necessary for short-term behavioral 
sensitization, but evidence suggests that the processes mediating long-term 
behavioral sensitization are not functional. Second, associative processes 
may be necessary for robust long-term behavioral sensitization. Thus, the 
associative deficits exhibited by preweanling rats may be the critical factor 
responsible for both the weaker sensitized response and the striking lack of 
persistence.   
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CHAPTER SEVEN 
PREWEANLING BEHAVIORAL SENSITIZATION:  
NEURAL MECHANISMS 
 
 In contrast to studies using adult rats and mice, there are relatively few 
studies examining the neural mechanisms mediating behavioral sensitization 
in preweanling rats. According to the few existing ontogenetic studies, it 
appears that the neural mechanisms governing the behavioral sensitization of 
preweanling rats may differ depending on the induction paradigm employed 
(one- vs. multi-trial).  
 
Dopamine Receptor Systems Underlying  
Behavioral Sensitization 
Multi-Trial Behavioral Sensitization 
 Although few studies have assessed dopaminergic involvement in the 
induction of multi-trial methamphetamine sensitization, none have examined 
the role of dopamine receptors in the expression of multi-trial 
methamphetamine sensitization. In terms of induction, administering a D2-like 
receptor antagonist during the pretreatment phase attenuates the multi-trial 
methamphetamine-induced behavioral sensitization of preweanling rats 
(Mohd-Yusof et al., 2016). Interestingly, concurrent pretreatment with both 
D1-like and D2-like receptor antagonists completely blocks the induction of 
multi-trial methamphetamine sensitization (Mohd-Yusof et al., 2016). In other 
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words, antagonizing both dopaminergic receptor types produces a greater 
effect on the sensitized behavioral response than antagonizing the D2 system 
alone. Unfortunately, there are no studies examining the induction or 
expression of multi-trial cocaine sensitization during the preweanling period.   
One-Trial Behavioral Sensitization 
 As mentioned above, the neural mechanisms underlying behavioral 
sensitization appear to differ depending on the paradigm used (one- vs. multi-
trial). For example, Mohd-Yusof et al. (2014) reported that D1-like receptor 
antagonism does not affect the induction of one-trial cocaine- or 
methamphetamine-induced behavioral sensitization in young rats. Likewise, 
D2-like receptor antagonism does not prevent the induction of one-trial 
methamphetamine-induced behavioral sensitization (Mohd-Yusof et al., 
2016). In contrast to the multi-trial paradigm, concurrent D1-like and D2-like 
receptor antagonism does not block the induction of one-trial 
methamphetamine sensitization (Mohd-Yusof et al., 2016). 
 Although little is known concerning the neural mechanisms underlying 
the expression of one-trial methamphetamine-induced behavioral 
sensitization, there is a limited amount of information about the expression of 
cocaine sensitization. Specifically, D1-like, but not D2-like, receptor 
antagonists attenuate the expression of cocaine-induced one-trial behavioral 
sensitization (McDougall, Rudberg, Veliz, Romero, Mohd-Yusof & Gonzalez, 
2016). Administering a combination of D1-like and D2-like receptor 
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antagonists on the test day causes a decline in the locomotor activity of 
preweanling rats, but it is uncertain whether this effect is due to the disruption 
of the sensitization process or a general motoric disturbance (McDougall et 
al., 2016). No studies have examined the expression of one-trial 
methamphetamine-induced behavioral sensitization. Overall, there is an 
unfortunate paucity of studies examining the involvement of the dopaminergic 
system in one- and multi-trial behavioral sensitization. 
 
Serotonin and Adrenergic Receptor Systems 
 Currently, there are no published studies that have examined whether 
serotonergic and adrenergic receptor systems mediate the induction and 
expression of behavioral sensitization during the preweanling period. The lack 
of such studies leaves an important void in our understanding of the ontogeny 
of behavioral sensitization.  
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CHAPTER EIGHT 
EEDQ 
 
 The drug N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) is a 
nonselective irreversible receptor antagonist (Meller, Goldstein, Friedhoff, & 
Schweitzer, 1988). Evidence suggests that EEDQ affects dopaminergic, 
serotonergic, and adrenergic receptors. First, Belleau, Martel, Lacasse, 
Ménard, Weinberg, and Perron (1968) discovered that EEDQ was an 
irreversible α-adrenergic receptor antagonist in smooth muscle. Later, Kalsner 
(1973) found that EEDQ was also effective in inactivating serotonergic 
receptors in rabbit aortic tissue. Finally, Hamblin and Creese (1983) reported 
that EEDQ was a potent and irreversible dopamine receptor antagonist.  
 More recently, studies have primarily focused on the effects of EEDQ 
in the central nervous system. For instance, homogenate binding studies 
revealed that 7.5 mg/kg EEDQ causes a 61-86% reduction in D1 and D2 
receptor densities in the caudate-putamen of adult rats (Crawford, McDougall, 
Rowlett, & Bardo, 1992). Importantly, Meller Bohmaker, Goldstein and 
Friedhoff (1985) reported that dopaminergic receptors can be protected from 
inactivation by injecting rats with selective dopamine receptor antagonists 
prior to EEDQ administration. In addition to its dopaminergic actions, EEDQ 
reduces 5-HT1A, 5-HT1B, 5-HT2, 5-HT1C, α2-adrenergic, GABA, and muscarinic 
receptor densities in various brain regions of rats (Adler, Meller, & Goldstein, 
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1985; Alper & Nelson, 2000; Miller, Lumpkin, Galpern, Greenblatt, & Shader, 
1991; Norman, Eubanks, & Creese, 1989; Pinto & Battaglia, 1993).      
 EEDQ can also be useful for investigating the neural mechanisms 
underlying behavior. For example, systemic or bilateral administration of 
EEDQ attenuates the dopamine agonist-induced locomotor activity of adult 
rats (Der-Ghazarian, Gutierrez, Varela, Herbert, Amodeo, Charntikov, 
Crawford, & McDougall, 2012; McDougall, Crawford, & Nonneman, 1992); 
whereas, unilateral administration of EEDQ in the caudate-putamen causes 
ipsilateral circling (Giorgi & Biggio, 1990a, 1990b). Additionally, EEDQ 
attenuates or completely blocks apomorphine- and NPA-induced stereotypy 
(Cameron & Crocker, 1989; Meller, Bordi, & Bohmaker, 1989). Therefore, it is 
clear that EEDQ-induced receptor inactivation attenuates the dopamine-
mediated behaviors of adult rats. 
 Because EEDQ is a nonselective irreversible antagonist, additional 
techniques are required to specify which receptor types mediate particular 
behaviors. As mentioned above, it is possible to protect one or more receptor 
types from the effects of EEDQ, thus allowing the actions of these receptors 
to be individually studied. For example, selectively inactivating D2-like 
receptors, but not D1-like receptors, inhibits apomorphine-induced stereotypy 
(Arnt, Hyttel, & Meier, 1988; Cameron & Crocker, 1988). Additionally, Arnt 
and Hyttel (1989) reported that selectively inactivating D1-like or D2-like 
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receptors in the caudate-putamen of adult rats attenuates the circling 
behavior produced by selective dopamine agonists.  
 Ineterestingly, few EEDQ studies have focused on learned behaviors, 
as opposed to unlearned behaviors (Arnt et al., 1988; Arnt & Hyttel, 1989; 
Der-Ghazarian, Widarma, Gutierrez, Amodeo, Valentine, Humphrey, 
Gonzalez, Crawford, & McDougall, 2014). Although, McDougall et al. (2016) 
have used EEDQ as a tool to assess whether D1-like and/or D2-like receptors 
mediate behavioral sensitization in preweanling rats. Based on the results of 
this study, it was reported that neither D1-like nor D2-like receptors mediate 
the induction of cocaine sensitization during the preweanling period. 
Unfortunately, the same study did not shed light on which receptor systems 
do mediate the induction of cocaine sensitization in preweanling rats 
(McDougall et al., 2016).  
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CHAPTER NINE 
SUMMARY AND THESIS STATEMENT 
 
 Behavioral sensitization is an important component of the addiction 
process (Robinson & Berridge, 1993). Several factors, such as age, induction 
paradigm (one- vs. multi-trial), and environmental context, influence the 
manifestation of behavioral sensitization. In terms of age, the behavioral 
sensitization of preweanling rats is less robust and persists for a much shorter 
period of time than it does in adults (Smith & Morrell, 2008; Tirelli et al., 2003).  
 The neural mechanisms underlying behavioral sensitization also differ 
depending on the psychostimulant used, the induction paradigm and, perhaps, 
age. For example, D1-like and D2-like receptor antagonists prevent the induction 
of one-trial cocaine-induced behavioral sensitization during adulthood (Fontana 
et al., 1993; Weiss et al., 1989), but not during the preweanling period (Mohd-
Yusof et al., 2014). The latter result suggests that some other receptor type 
mediates the induction of behavioral sensitization in preweanling rats. 
Suggestively, Auclair et al. (2004) reported that serotonin and adrenergic 
receptor antagonists inhibit the induction and expression of behavioral 
sensitization in adult mice. Unfortunately, no studies have examined the 
importance of serotonergic and adrenergic systems for the induction or 
expression of behavioral sensitization during the preweanling period.  
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 The purpose of this thesis was to assess the involvement of the 
serotonergic and adrenergic systems in the induction and expression of one-trial 
cocaine-induced behavioral sensitization. Rats were assessed during the late 
preweanling period (PD 18-21), when cocaine sensitization is most robust 
(Kozanian et al., 2012). The aims of this thesis were two-fold: first, to determine 
whether EEDQ prevents the induction or expression of one-trial cocaine 
sensitization. It was hypothesized that EEDQ would prevent both the induction 
and expression of one-trial cocaine sensitization. This hypothesis was based on 
combined evidence that the dopaminergic, serotonergic, and adrenergic receptor 
systems mediate behavioral sensitization. 
The second goal of this thesis was to differentiate among the receptor 
types and determine whether 5-HT and/or 𝛼1-adrenergic receptors mediate the 
induction and/or expression of cocaine sensitization during the preweanling 
period. It was hypothesized that both 5-HT and 𝛼1-adrenergic receptor 
stimulation will be necessary for the induction and expression of behavioral 
sensitization. This hypothesis was based on evidence from the adult mouse 
literature showing that each of these receptor types is involved in the induction 
and expression of multi-trial psychostimulant-induced behavioral sensitization 
(Auclair et al., 2004). 
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CHAPTER TEN 
MATERIALS AND METHODS 
 
Subjects 
 Subjects were 320 (n=8 per group) young male and female rats of 
Sprague–Dawley descent (Charles River, Hollister, CA) that were born and 
raised at California State University, San Bernardino (CSUSB). Litters were 
culled to ten pups on PD 3. Rats were housed in large polycarbonate maternity 
cages (30.5 × 43 × 19 cm) on a ventilated rack. Food and water was freely 
available. The colony room was maintained at 22–23 °C and kept under a 12:12 
light/dark cycle. Except during testing, rats were kept with the dam and 
littermates. Testing was done in a separate experimental room and was 
conducted during the light phase of the cycle. Subjects were cared for according 
to the “Guide for the Care and Use of Laboratory Animals” (National Research 
Council, 2010) under a research protocol approved by the Institutional Animal 
Care and Use Committee of CSUSB.  
 
Apparatus 
 Behavioral testing was done in activity monitoring chambers (25.5 × 25.5 
× 41 cm) that consist of acrylic walls, a plastic floor, and an open top (Coulbourn 
Instruments, Whitehall, PA). Each chamber includes an X–Y photobeam array, 
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with 16 photocells and detectors, that was used to determine distance traveled (a 
measure of locomotor activity).  
 
Drugs 
 EEDQ was dissolved in a 50% DMSO solution (1:1 (v/v) in distilled water), 
while (-)-cocaine hydrochloride and prazosin hydrochloride were dissolved in 
saline. Ritanserin was dissolved in a minimal amount of glacial acetic acid (15 
µl/ml) and diluted in saline. All drugs were purchased from Sigma-Aldrich (St. 
Louis, MO) and injected intraperitoneally (IP) at a volume of 5 ml/kg.  
 
Procedure 
Experiment 1: Effects of EEDQ on the Induction of One-Trial  
Cocaine-Induced Behavioral Sensitization 
 On the preinjection day (PD 18), rats were injected with EEDQ (0, 7.5, or 
15 mg/kg) and immediately returned to their home cage. On the pretreatment 
day, which occurred 24 h later (PD 19), half of the rats in each group were 
injected with saline and the other half received 30 mg/kg cocaine. Immediately 
afterwards, rats were placed in activity chambers for 30 min and distance 
traveled was recorded. On the test day (PD 21), all rats (n=8 per group) were 
injected with 20 mg/kg cocaine and placed in activity chambers for 120 min. The 
design of Experiment 1 is shown in Table 1.  
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Experiment 2a: The Use of 5-HT and/or α1-Adrenergic Receptor  
Protection to Assess the Effects of EEDQ on the Induction of  
One-Trial Cocaine-Induced Behavioral Sensitization 
 On the preinjection day (PD 18), rats first received a protection injection of 
prazosin (25 mg/kg), ritanserin (3 mg/kg), prazosin+ritanserin, or saline in the 
home cage. After 30 min, rats received a preinjection of EEDQ (15 mg/kg). A 
separate control group received a protection injection of saline and a preinjection 
of vehicle. On the pretreatment day, which occurred 24 h later (PD 19), half of 
the rats in each group received saline and the other half received 30 mg/kg 
cocaine. Immediately afterwards, rats were placed in activity chambers for 30 
min and distance traveled was recorded.  
Table 1. Design of Experiment 1 
Group Treatment (Age)   
 Preinjection Pretreatment Day Test Day 
 (PD 18) (PD 19) (PD 21) 
Acute Control Group Vehicle Saline Cocaine 
Sensitization Control 
Group 
Vehicle Cocaine Cocaine 
7.5 mg/kg EEDQ Acute 
Control 
7.5 mg/kg EEDQ Saline Cocaine 
7.5 mg/kg EEDQ 
Sensitization  
7.5 mg/kg EEDQ Cocaine Cocaine 
15 mg/kg EEDQ Acute 
Control 
15 mg/kg EEDQ Saline Cocaine 
15 mg/kg EEDQ 
Sensitization 
15 mg/kg EEDQ Cocaine Cocaine 
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On the test day (PD 21), all rats (n=8 per group) were injected with 20 mg/kg 
cocaine and placed in activity chambers for 120 min. The design of Experiment 
2a is shown in Table 2. 
Experiment 2b: Effects of Ritanserin and Prazosin on the Induction  
of One-Trial Cocaine Sensitization 
 A separate four group experiment was conducted to determine whether 
the protection treatments affected the locomotor activity of nonEEDQ-treated 
rats. On the preinjection day (PD 18), rats first received an injection of saline or 
prazosin+ritanserin in the home cage. After 30 min, all rats received a 
preinjection of vehicle. On the pretreatment day, which occurred 24 h later (PD 
19), half of the rats in each group received saline and the other half received 30 
mg/kg cocaine. Immediately afterwards, rats were placed in activity chambers for 
30 min and distance traveled was recorded. On the test day (PD 21), all rats (n=6 
per group) were injected with 20 mg/kg cocaine and placed in activity chambers 
for 120 min. The design of Experiment 2b is shown in Table 3. 
Experiment 3: Effects of EEDQ on the Expression of One-Trial  
Cocaine-Induced Behavioral Sensitization  
 On the pretreatment day (PD 19), rats were injected with saline or 30 
mg/kg cocaine and placed in activity chambers for 30 min. On the preinjection 
day, which occurred 24 h later (PD 20), an equal number of saline- and cocaine-
pretreated rats were injected with 0, 7.5, or 15 mg/kg EEDQ and immediately 
returned to their home cage. On the test day (PD 21), all rats (n=8 per group) 
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Table 2. Design of Experiment 2a 
Group Treatment (Age)    
 Protection  Preinjection Pretreatment 
Day 
Test Day 
 (PD 18) (PD 18) (PD 19) (PD 21) 
Acute Control 
Group 
Saline Vehicle Saline Cocaine 
Nonprotected-
EEDQ Acute 
Control 
Saline EEDQ Saline Cocaine 
Adrenergic 
Protected-EEDQ 
Acute Control 
Prazosin EEDQ Saline Cocaine 
5-HT Protected-
EEDQ Acute 
Control 
Ritanserin EEDQ Saline Cocaine 
Adrenergic/5-HT 
Protected-EEDQ 
Acute Control 
Prazosin+ 
Ritanserin 
EEDQ Saline Cocaine 
Sensitization 
Control Group 
Saline Vehicle Cocaine Cocaine 
Nonprotected-
EEDQ 
Sensitization 
Saline EEDQ Cocaine Coaine 
Adrenergic 
Protected-EEDQ 
Sensitization 
Prazosin EEDQ Cocaine Cocaine 
5-HT Protected-
EEDQ 
Sensitization 
Ritanserin EEDQ Cocaine Cocaine 
Adrenergic/5-HT 
Protected-EEDQ 
Sensitization 
Prazosin+ 
Ritanserin 
EEDQ Cocaine Cocaine 
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Table 3. Design of Experiment 2b 
Group Treatment 
(Age) 
   
 Preinjection (1) Preinjection (2) Pretreatment 
Day 
Test Day 
 (PD 18) (PD 18) (PD 19) (PD 21) 
Acute Control 
Group 
Saline Vehicle Saline Cocaine 
Sensitization 
Control Group 
Saline Vehicle Cocaine Cocaine 
Adrenergic/5-HT 
Antagonist Acute 
Control 
Prazosin+ 
Ritanserin 
Vehicle Saline Cocaine 
Adrenergic/5-HT 
Antagonist 
Sensitization 
Prazosin+ 
Ritanserin 
Vehicle Cocaine Cocaine 
 
were injected with 20 mg/kg cocaine and placed in activity chambers for 120 min. 
The design of Experiment 3 is shown in Table 4. 
Experiment 4a: The Use of 5-HT and/or α1-Adrenergic Receptor  
Protection to Assess the Effects of EEDQ on the Expression of  
One-Trial Cocaine-Induced Behavioral Sensitization 
 On the pretreatment day (PD 19), rats were injected with saline or 30 
mg/kg cocaine and placed in activity chambers for 30 min. On the preinjection 
day, which occurred 24 h later (PD 20), rats received a protection injection of 
prazosin (25 mg/kg), ritanserin (3 mg/kg), prazosin+ritanserin, or saline in the 
home cage. After 30 min, rats received a preinjection of EEDQ (15 mg/kg). A 
separate control group received a protection injection of saline and a preinjection 
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Table 4. Design of Experiment 3 
Group Treatment (Age)   
 Pretreatment Day Preinjection Test Day 
 (PD 19) (PD 20) (PD 21) 
Acute Control 
Group 
Saline Vehicle Cocaine 
Sensitization 
Control Group 
Cocaine Vehicle Cocaine 
7.5 mg/kg EEDQ 
Acute Control 
Saline 7.5 mg/kg EEDQ Cocaine 
7.5 mg/kg EEDQ 
Sensitization  
Cocaine 7.5 mg/kg EEDQ Cocaine 
15 mg/kg EEDQ 
Acute Control 
Saline 15 mg/kg EEDQ Cocaine 
15 mg/kg EEDQ 
Sensitization 
Cocaine 15 mg/kg EEDQ Cocaine 
 
of vehicle. On the test day (PD 21), all rats (n=8 per group) were injected with 20 
mg/kg cocaine and placed in activity chambers for 120 min. The design of 
Experiment 4a is shown in Table 5. 
Experiment 4b: Effects of Ritanserin and Prazosin on the  
Expression of One-Trial Cocaine Sensitization 
 Another four group experiment was conducted to determine whether the 
protection treatments affected the locomotor activity of nonEEDQ-treated rats. 
On the pretreatment day, which occurred 24 h later (PD 19), half of the rats in 
each group received saline and the other half received 30 mg/kg cocaine. 
Immediately afterwards, rats were placed in activity chambers for 30 min and 
distance traveled was recorded. On the preinjection day (PD 20), rats first 
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received an injection of saline or prazosin+ritanserin in the home cage. After 30 
min, all rats received a preinjection of vehicle. On the test day (PD 21), all rats 
(n=8 per group) were injected with 20 mg/kg cocaine and placed in activity 
chambers for 120 min. The design of Experiment 4b is shown in Table 6. 
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Table 5. Design of Experiment 4a 
Group Treatment 
(Age) 
   
 Pretreatment 
Day 
Protection  Preinjection Test Day 
 (PD 19) (PD 20) (PD 20) (PD 21) 
Acute Control 
Group 
Saline Saline Vehicle Cocaine 
Nonprotected-
EEDQ Acute 
Control 
Saline Saline EEDQ Cocaine 
Adrenergic 
Protected-EEDQ 
Acute Control 
Saline Prazosin EEDQ Cocaine 
5-HT Protected-
EEDQ Acute 
Control 
Saline Ritanserin EEDQ Cocaine 
Adrenergic/5-HT 
Protected-EEDQ 
Acute Control 
Saline Prazosin+ 
Ritanserin 
EEDQ Cocaine 
Sensitization 
Control Group 
Cocaine Saline Vehicle Cocaine 
Nonprotected-
EEDQ Sensitization 
Cocaine Saline EEDQ Coaine 
Adrenergic 
Protected-EEDQ 
Sensitization 
Cocaine Prazosin EEDQ Cocaine 
5-HT Protected-
EEDQ Sensitization 
Cocaine Ritanserin EEDQ Cocaine 
Adrenergic/5-HT 
Protected-EEDQ 
Sensitization 
Cocaine Prazosin+ 
Ritanserin 
EEDQ Cocaine 
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Table 6. Design of Experiment 4b 
Group Treatment 
(Age) 
   
 Pretreatment 
Day 
Preinjection 
(1) 
Preinjection (2) Test Day 
 (PD 19) (PD 20) (PD 20) (PD 21) 
Acute Control Group Saline Saline Vehicle Cocaine 
Sensitization Control 
Group 
Cocaine Saline Vehicle Cocaine 
Adrenergic/5-HT 
Antagonist Acute 
Control 
Saline Prazosin+ 
Ritanserin 
Vehicle Cocaine 
Adrenergic/5-HT 
Antagonist 
Sensitization 
Cocaine Prazosin+ 
Ritanserin 
Vehicle Cocaine 
 
Data Analysis 
 To statistically analyze data from both the pretreatment and test days, 
distance traveled data was analyzed using one-way or factorial analyses of 
variance (ANOVA) depending on experiment. For example, the test day of 
Experiment 2a was analyzed using a 5 × 2 × 12 (preinjection × pretreatment × 
time block) mixed factorial ANOVA, with the preinjection and pretreatment 
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variables being between-subject factors and time block being a within-subject 
repeated measures factor. The Huynh-Feldt epsilon statistic was used to adjust 
degrees of freedom when the assumption of sphericity was violated (Huynh & 
Feldt, 1976), as determined by Mauchly’s test of sphericity. Corrected degrees of 
freedom were rounded to the nearest whole number. When further analyzing 
statistically significant higher order interactions, the mean square error terms 
(i.e., MSerror) used for the Tukey calculations was based on separate one-way 
ANOVAs at each time block.  
 Litter effects were minimized by assigning no more than one subject from 
each litter to a particular group (for a discussion of litter effects, see Zorrilla, 
1997). Young rats do not typically exhibit sex differences after psychostimulant 
treatment (Bowman, Blatt, & Kuhn, 1997; Frantz, Babcock, & Van Hartesveldt, 
1996; McDougall et al., 2013; Snyder, Katovic, & Spear, 1998), so sex was not 
included as a factor in the statistical analysis.  
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CHAPTER ELEVEN 
RESULTS 
 
Experiment 1: Effects of EEDQ on the Induction of One-Trial  
Cocaine-Induced Behavioral Sensitization 
Pretreatment Day 
  On the pretreatment day, rats given cocaine (M = 7439.16 cm, SEM = 
716.08) had greater locomotor activity than rats given saline (M = 2639.40 cm, 
SEM = 392.53) (Figure 1, upper graph) [Drug effect, F(1,47)=36.76, p<0.001]. 
EEDQ treatment did not significantly affect locomotion, although a nonsignificant 
decline in locomotor activity was observed in rats treated with the higher dose of 
EEDQ (15 mg/kg).  
Test Day 
 On the test day, locomotor sensitization was evident (Figure 1, lower graph) 
since rats in the 0 mg/kg EEDQ-sensitization group had significantly greater 
locomotor activity than rats in the 0 mg/kg EEDQ-acute control group 
[Preinjection × Drug Interaction, F(2,47)=5.90, p<0.01; and Tukey tests, 
p<0.001]. Both the low (7.5 mg/kg) and high doses (15 mg/kg) of EEDQ 
significantly attenuated sensitized locomotor activity [Tukey tests, p<0.05]. A 
separate Preinjection × Time Block ANOVA comparing only the sensitized 
groups showed that EEDQ significantly reduced locomotor activity during time 
blocks 1-9 [Preinjection × Time Block interaction, F(7,76)=2.84, p<0.05; and 
Tukey tests, p<0.05]. 
  
   57 
Experiment 2a: The Use of 5-HT and/or α1-Adrenergic Receptor  
Protection to Assess the Effects of EEDQ on the  
Induction of One-Trial Cocaine-Induced 
 Behavioral Sensitization 
Pretreatment Day  
 On the pretreatment day, rats that received cocaine (M = 6361.51 cm, SEM 
= 466.18) showed significantly more locomotor activity than rats given saline (M 
= 2763.78 cm, SEM = 345.09) (Figure 2, upper graph) [Drug main effect, 
F(1,70)= 42.28, p<0.001]. Treatment with prazosin, ritanserin, and EEDQ did not 
significantly affect locomotor activity on the pretreatment day.  
Test Day 
  On the test day, it is clear that sensitization occurred since cocaine-
pretreated rats in the Sal-DMSO group (i.e., the Sensitization Control group) had 
significantly more locomotor activity counts than saline-pretreated rats in the Sal-
DMSO group (i.e., the Acute Control group) (right panels, Figure 2) [Preinjection 
× Drug interaction, F(4,70)=3.62, p<0.05; and Tukey tests, p<0.05]. Among the 
saline-pretreated groups, EEDQ did not affect locomotion. Among the cocaine-
pretreated groups, EEDQ significantly reduced locomotor activity, with the 
decline being most evident in the Praz-EEDQ group [Tukey tests, p<0.05]. 
Overall, both the Preinjection and Drug variables interacted with time block to 
affect behavior (left panels, Figure 2) [Preinjection × Time Block interaction, 
F(19,333)=3.35, p<0.001; Drug × Time Block interaction, F(5,333)=3.08, p<0.05]. 
A separate analysis of only the cocaine-pretreated groups (i.e., the Sensitization 
groups) showed that EEDQ significantly reduced locomotor activity on time 
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blocks 1–7 relative to the DMSO controls (lower graph, left panel, Figure 2) 
[EEDQ × Time Block interaction, F(4,162)=8.49, p<0.001; and Tukey tests, 
p<0.05]. 
Experiment 2b: Effects of Ritanserin and Prazosin on the  
Induction of One-Trial Cocaine Sensitization 
Pretreatment Day  
Rats that received cocaine (M = 6573.22 cm, SEM = 540.71) showed 
significantly more locomotor activity than rats given saline (M = 1964.36 cm, SEM 
= 318.22) (Figure 3, upper graph) [Drug main effect, F(1,23)= 76.48, p<0.001]. 
Locomotor activity was not significantly affected by combined treatment with 
prazosin and ritanserin.  
Test Day 
 On the test day, sensitization was not observed because cocaine-pretreated 
rats in the saline group (i.e., the Sensitization Control group; M = 45110.70 cm, 
SEM = 7419.72) exhibited only marginally more locomotor activity than saline-
pretreated rats in the saline group (i.e., the Acute Control group; M = 26541.95 
cm, SEM = 6093.54) [Preinjection × Drug interaction, F(1,20)= 3.56, p=0.074] 
(lower graph, right panels, Figure 3). Combined treatment with the two 
antagonists did not affect locomotor activity; however, there was a trend for  
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Figure 1. Experiment 1. Mean distance traveled (±SEM) on the pretreatment and 
test day. On the preinjection day (PD 18), rats were injected with EEDQ (0, 7.5, 
or 15 mg/kg). On pretreatment day (PD 19), rats were injected with saline or 30 
mg/kg cocaine, immediately followed by 30 min of behavioral assessment. On 
the test day (PD 21), all rats were injected with 20 mg/kg cocaine, immediately 
followed by 120 min of behavioral assessment. * Significantly different from the 0 
mg/kg EEDQ-Saline group (acute control group; open circles and open bars). † 
Significantly different from the 0 mg/kg EEDQ-cocaine group (cocaine alone 
group; filled circles and black bars). 
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Figure 2. Experiment 2a. Mean distance traveled (±SEM) on the pretreatment 
and test day. On the preinjection day (PD 18), rats were injected with prazosin (5 
mg/kg), ritanserin (5 mg/kg), prazosin+ritanserin, or saline in the home cage. 
After 30 min, rats received a preinjection of EEDQ (15 mg/kg). On the 
pretreatment day (PD 19), rats were injected with saline or 30 mg/kg cocaine, 
immediately followed by 30 min of behavioral assessment. On the test day (PD 
21), all rats were injected with 20 mg/kg cocaine, immediately followed by 120 
min of behavioral assessment. * Significantly different from the Saline-DMSO 
Acute Control group (open bar). † Significantly different from the Saline-DMSO 
Sensitization group (filled bar, filled circles). 
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prazosin+ritanserin to enhance the locomotor activity of saline-pretreated rats 
and depress the locomotion of cocaine-pretreated rats. 
Experiment 3: Effects of EEDQ on the Expression of One-Trial  
Cocaine-Induced Behavioral Sensitization 
 On the pretreatment day, rats given cocaine (M = 8054.65 cm, SEM = 
343.22) had greater locomotor activity than rats given saline (M = 2118.44 cm, 
SEM = 217.77) [t(46)= 14.60, p<0.001]. On the test day, locomotor sensitization 
was apparent since the 0 mg/kg EEDQ-sensitization group exhibited significantly 
more locomotor activity than the 0 mg/kg EEDQ-acute control group [Preinjection 
× Drug Interaction, F(2,47)= 5.74, p<0.01; and Tukey tests, p<0.05] (Figure 4). 
Both the low (7.5 mg/kg) and high (15 mg/kg) doses of EEDQ significantly 
attenuated locomotor activity, because the 7.5 mg/kg EEDQ-sensitization group 
and the 15 mg/kg EEDQ-sensitization group had significantly less locomotor 
activity than the 0 mg/kg EEDQ-sensitization group [Preinjection × Drug 
Interaction]. Moreover, the EEDQ-sensitization groups were not different from the 
acute control group. 
Experiment 4a: The Use of 5-HT and/or α1-Adrenergic Receptor 
 Protection to Assess the Effects of EEDQ on the 
 Expression of One-Trial Cocaine-Induced  
Behavioral Sensitization 
 On the pretreatment day, rats that received cocaine (M = 7691.17 cm, SEM 
= 331.28) had significantly more locomotor activity than rats given saline (M = 
2593.23 cm, SEM = 219.26) [t(78)= 12.832, p<0.001]. On the test day, locomotor 
sensitization was not apparent since cocaine-pretreated rats (M = 28456.66 cm, 
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SEM = 1707.44) exhibited only marginally more locomotor activity than saline-
pretreated rats (M = 24026.85 cm, SEM = 1702.95) [Preinjection main effect, 
F(1,70)= 3.74, p=0.057] (right panels, Figure 5). A separate statistical analysis 
comparing only the saline-pretreated and cocaine-pretreated Sal-DMSO groups 
also indicated an absence of behavioral sensitization. Neither EEDQ or the 
protection treatments significantly affected performance on the test day 
[Preinjection main effect, F(4,70)= 2.49, p=0.052]. 
Experiment 4b: Effects of Ritanserin and Prazosin on the  
Expression of One-Trial Cocaine Sensitization 
 On the pretreatment day, rats given cocaine (M = 8214.45 cm, SEM = 
548.58) had significantly more locomotor activity than rats that received saline (M 
= 2788.30 cm, SEM = 383.31) [t(22)= 8.11, p<0.001]. On the test day, locomotor 
sensitization was evident since rats in the saline-sensitization group had 
significantly greater locomotor activity than rats in the saline-acute control group 
[Preinjection × Drug interaction, F(1,20)= 6.53, p<0.05] (right panels, Figure 6). 
In addition, sensitized rats preinjected with prazosin and ritanserin had 
significantly less locomotor activity than those that received a preinjection of 
saline [Preinjection × Drug interaction]. None of the interactions involving the 
time block variable were statistically significant.  
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Figure 3. Experiment 2b. Mean distance traveled (±SEM) on the pretreatment 
and test day. On the preinjection day (PD 18), rats were injected with 
prazosin+ritanserin or saline in the home cage. After 30 min, rats received an 
injection of vehicle. On the pretreatment day (PD 19), rats were injected with 
saline or 30 mg/kg cocaine, immediately followed by 30 min of behavioral 
assessment. On the test day (PD 21), all rats were injected with 20 mg/kg 
cocaine, immediately followed by 120 min of behavioral assessment. * 
Significantly different from the Saline control group (open bar). 
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Figure 4. Experiment 3. Mean Distance traveled (±SEM) on the test day. On 
the pretreatment day (PD19), rats were injected with saline or 30 mg/kg 
cocaine, immediately followed by 30 min of behavioral assessment. On the 
preinjection day (PD 20), rats were injected with EEDQ (0, 7.5, or 15 mg/kg) in 
the home cage. On the test day (PD 21), all rats were challenged with 20 
mg/kg cocaine followed immediately by 120 min of behavioral assessment. * 
Significantly different from 0 mg/kg EEDQ-Saline group (acute control group; 
open circles and open bars). † Significantly different from the 0 mg/kg EEDQ-
cocaine group (cocaine alone group; filled circles and black bars). 
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Figure 5. Experiment 4a. Mean distance traveled (±SEM) on the test day. On the 
pretreatment day (PD 19), rats were injected with saline or 30 mg/kg cocaine, 
immediately followed by 30 min of behavioral assessment. On the preinjection 
day (PD 20), rats were injected with prazosin (5 mg/kg), ritanserin (5 mg/kg), 
prazosin+ritanserin, or saline in the home cage. After 30 min, rats received a 
preinjection of EEDQ (15 mg/kg). On the test day (PD 21), all rats were injected 
with 20 mg/kg cocaine, immediately followed by 120 min of behavioral 
assessment.  
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Figure 6. Experiment 4b. Mean distance traveled (±SEM) on the test day. On the 
pretreatment day (PD 19), rats were injected with saline or 30 mg/kg cocaine, 
immediately followed by 30 min of behavioral assessment. On the preinjection 
day (PD 20), rats were injected with prazosin+ritanserin or saline in the home 
cage. After 30 min, rats received an injection of vehicle. On the test day (PD 21), 
all rats were injected with 20 mg/kg cocaine, immediately followed by 120 min of 
behavioral assessment. * Significantly different from the Saline control group 
(open bar). † Significantly different from the Saline Sensitization group (filled 
bar).  
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CHAPTER TWELVE 
DISCUSSION 
 
 Prior to this thesis, research examining the mechanisms underlying 
cocaine-induced one-trial behavioral sensitization in preweanling rats was 
scarce (e.g., see McDougall et al., 2016; Mohd-Yusof et al., 2014; 2016); 
however, multiple studies using adult rats indicated that dopaminergic, 
serotonergic, and adrenergic receptor systems are involved in the mediation 
of behavioral sensitization (Auclair et al., 2004; O’Neill et al., 1999; 
Vanderschuren et al., 2003). Behavioral and neurochemical data using 
preweanling rats suggest that selective protection from the nonspecific 
irreversible antagonist EEDQ could be useful for investigating the role of 
individual receptor types in behavioral sensitization (McDougall et al., 2016). 
Therefore, in the present thesis I used EEDQ in conjunction with selective 
protection experiments to examine whether the serotonergic and adrenergic 
receptor systems mediate the induction and expression of cocaine-induced 
one-trial behavioral sensitization in preweanling rats. 
 Results from this thesis showed that cocaine was able to induce one-
trial behavioral sensitization in preweanling rats. By administering EEDQ 
prior to either the pretreatment day or the test day, it was apparent that 
general receptor inactivation blocked both the induction and expression of 
cocaine-induced one-trial behavioral sensitization. Importantly, administering 
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prazosin and ritanserin prior to EEDQ treatment did not protect the induction 
or expression of behavioral sensitization, which suggests that serotonergic 
and adrenergic receptors do not mediate cocaine-induced sensitized 
responding in preweanling rats. This negative result indicates that some 
other receptor type, or a combination of redundant receptor systems, 
mediates the induction and expression of behavioral sensitization (see also 
White et al., 1998). 
 Some findings from this study were unexpected. For example, it was 
concerning that cocaine did not induce a statistically significant sensitized 
response in Experiments 2b and 4a. In the case of Experiment 2b, there 
were only six subjects per group, as opposed to the eight subjects per group 
that we normally use. This lack of power may have been responsible for the 
inability to detect behavioral sensitization. Interestingly, the magnitude of the 
effect size between the Acute Control group and the Sensitization group of 
Experiment 2b is similar to, if not greater than, experiments in which 
statistically significant behavioral sensitization was observed. For example, 
the effect size magnitude was 18568.75 cm in Experiment 2b, which resulted 
in a nonsignificant difference; whereas, the effect size magnitude between 
the Acute Control and Sensitization group of Experiment 4b was 17137.88 
cm, which was sufficient for a statistically significant effect. In the case of 
Experiment 4a, the reason for the marginal sensitized responding is more 
unclear. Perhaps the fact that this experiment examined the expression 
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(rather than the induction) of behavioral sensitization was responsible for the 
weakened sensitization effect. More specifically, the nature of the expression 
paradigm may have led to increased stress on the control animals (i.e., the 
induction paradigm requires fewer injections on PD 20 and 21 than the 
expression paradigm), which may have affected our ability to detect cocaine-
induced behavioral sensitization. Indeed, stress-induced behavioral 
sensitization is a well known phenomenon that can be initiated by the 
injection protocol itself (for a review, see Robinson & Becker, 1986). That 
being said, Experiment 4b was also an expression experiment, with the 
same number and timing of injections, and statistically significant behavioral 
sensitization was achieved. Therefore, it is uncertain why cocaine-induced 
behavioral sensitization was not evident in Experiment 4a. In the same 
experiment, EEDQ did not block behavioral sensitization; however, since a 
statistically significant sensitized response did not occur, it is reasonable to 
argue that EEDQ could not block a phenomenon that was not present. Even 
so, close examination of the data reveals that EEDQ did not appear to cause 
a robust decline in the locomotor activity of the “sensitization” groups.  
 Finally, it is concerning that prazosin and ritanserin affected the 
locomotor activity and sensitized responding of cocaine-treated rats 
independent of the actions of EEDQ (see Experiments 2b and 4b). The 
results of Experiment 2a suggest that neither the serotonergic or adrenergic 
receptor systems are responsible for one-trial cocaine-induced behavioral 
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sensitization, because protecting these specific receptors from EEDQ failed 
to keep behavioral sensitization intact. The results of Experiment 2b and 4b 
challenge this conclusion, as the absence of behavioral sensitization may 
have been due to the drugs used to protect the serotonergic and adrenergic 
receptors. It is unclear whether it was prazosin or ritanserin that weakened 
sensitized responding, since these drugs were co-administered in the control 
experiments (2b and 4b). Testing the effects of prazosin or ritanserin alone 
on cocaine-induced one-trial behavioral sensitization would resolve this 
issue. Additional improvements for future studies would include using 
different serotonergic and adrenergic antagonists, as well as novel methods 
of receptor protection.  
 The finding that prazosin and ritanserin caused prolonged changes in 
cocaine-induced behavioral sensitization is interesting in its own right and 
deserves consideration. The most obvious possibility is that these 
serotonergic and adrenergic compounds altered the functioning of the 
dopaminergic system, which resulted in the observed changes in locomotor 
activity. For example, 5-HT2 receptor antagonism by ritanserin potentiates 
amphetamine-induced dopamine release in adult rats (Pehek & Bi, 1997). In 
addition, prazosin decreases dopamine transmission in the reward pathway 
(Zhang & Kosten, 2005). Therefore, ritanserin and prazosin may impact both 
cocaine-induced locomotor activity and behavioral sensitization by altering 
normal dopaminergic functioning. 
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 In addition to the uncertainty regarding the effects of prazosin and 
ritanserin on behavioral sensitization, we did not demonstrate that these 
drugs protected adrenergic and serotonergic receptors from the alkylating 
effects of EEDQ. Although previous receptor binding experiments show that 
5 mg/kg prazosin and 1 mg/kg ritanserin protect adrenergic and serotonergic 
receptors, respectively, from alkylation by EEDQ, the animals used in these 
studies were adult rats (Giorgi & Biggio, 1990; Kettle, Cheetham, Martin, 
Prow, & Heal, 1999). Given the many ontogenetic differences involving the 
serotonergic and adrenergic receptor systems (e.g., Auclair et al., 2004; 
Drouin et al., 2002), there is the possibility that these compounds may not 
have the same protective effects in preweanling rats. In the future, it would 
be advantageous to conduct a receptor binding study to confirm the 
protective effects of prazosin and ritanserin in preweanling rats. In addition, 
the combined use of these drugs, in conjunction with EEDQ, may be 
producing an effect that interferes with behavioral sensitization. For example, 
in Experiments 2b and 4b, it is clear that antagonizing serotonergic and 
adrenergic receptors reduces locomotor activity. This evidence indicates that 
serotonergic and adrenergic receptor stimulation is necessary for the 
induction and expression of behavioral sensitization; however, the results of 
Experiments 2a and 4a do not support this conclusion. Therefore, the 
combined effects of ritanserin, prazosin, and EEDQ should be further 
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examined, and in future experiments, different drugs that do not have 
complex interactions should be considered.  
 It is well established that the neural mechanisms underlying behavioral 
sensitization differ depending on the psychostimulant drug being used (e.g., 
cocaine vs. amphetamine; see Vanderschuren & Kalivas, 2000; White et al., 
1998). For example, Auclair et al. (2004) reported that serotonergic and 
adrenergic receptor antagonists prevent the induction and expression of 
amphetamine-induced behavioral sensitization in adult mice; whereas, I 
found that the same drugs did not affect cocaine-induced behavioral 
sensitization in preweanling rats. The reason for such psychostimulant-
specific effects may lie in the mechanism of action for each drug. In general, 
amphetamine-like compounds affect brain function by enhancing the 
transmission of monamines like serotonin, norepinephrine, and dopamine 
(Shi, Pun, Zhang, Jones, & Bunney, 2000). Specifically, amphetamine blocks 
the reuptake of monoamines, while also increasing cytoplasmic dopamine 
concentrations via reverse receptor transport (Fleckenstein & Hanson, 
2003). In contrast, cocaine increases extracellular monoamine levels through 
the sole mechanism of blocking monoamine reuptake transporters (Meyer & 
Quenzer, 2005; Vanderschuren & Kalivas, 2000).  
 Auclair et al. (2004) also reported that serotonergic and adrenergic 
receptor antagonists block the induction and expression of cocaine-induced 
behavioral sensitization. In the Auclair et al. (2004) experiment, adult mice 
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were used as opposed to preweanling rats. These discrepant results leave 
open the possibility that there are ontogenetic or species-based differences 
in the mechanisms mediating behavioral sensitization. Although species 
differences in behavioral sensitization are seldom reported, pronounced age-
dependent differences in sensitized responding are well-established (for a 
review, see Tirelli et al., 2003). For example, one-trial behavioral 
sensitization persists for months in adult rats, while only lasting a few days in 
preweanling rats (McDougall et al., 2009; Robinson et al., 1982; Valjent et 
al., 2010). In addition, drug-environment associations are necessary for the 
one-trial behavioral sensitization of adult rats (Weiss et al., 1989), while 
environmental context does not influence the one-trial sensitized responding 
of preweanling rats (McDougall et al., 2009). Finally, D1-like antagonists 
block the induction of one-trial behavioral sensitization in adult rats, but not in 
preweanling rats (Mattingly et al., 1991; Mohd-Yusof et al., 2014; Kuribara, 
1995; Valjent et al., 2010).  
 In addition to ontogenetic and species-based differences in the 
mechanisms underlying behavioral sensitization, there also appear to be 
ontogenetic differences in the actions of EEDQ. For example, EEDQ blocks 
behavioral sensitization in preweanling rats and locomotor activity in adults, 
but this alkylating agent does not reduce locomotor activity in the younger 
age group (Der-Ghazarian et al., 2014; McDougall, Valentine, Gonzalez, 
Humphrey, Widarma, & Crawford, 2014). These findings suggest that the 
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mechanisms mediating locomotor activity in preweanling rats are resistant to 
EEDQ, while the mechanisms mediating behavioral sensitization are not. 
The inability of EEDQ to block the locomotor activity of preweanling rats is 
interesting, and may be due to a compensatory mechanism involving an 
excess of high affinity D2-like receptors that is absent in older animals 
(McDougall et al., 2014). Consistent with this explanation, preweanling rats 
have a higher percentage of high affinity striatal D2-like receptors (i.e., D2High 
receptors) than adolescent or adult animals (McDougall et al., 2015). 
 Although thousands of studies have examined the neural bases of 
behavioral sensitization, it remains unclear which receptor systems are 
important for the induction and expression of cocaine-induced behavioral 
sensitization. Despite contradictory evidence, it is still possible that 
dopaminergic, serotonergic, and adrenergic receptor systems all play a role 
in behavioral sensitization. In the typical study, investigation of these 
receptor systems has been restricted to antagonism or stimulation of 
individual receptor types. Instead, it is probable that many neurotransmitter 
systems work simultaneously, and perhaps redundantly, to mediate the 
complex process that is behavioral sensitization. Since it is likely that there 
are many neurotransmitter systems involved in the mediation of behavioral 
sensitization, antagonizing only a single receptor type may not have a great 
effect on the overall sensitization process. In other words, when one 
particular neurotransmitter system is antagonized, another neurotransmitter 
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system may compensate in order to keep the behavior intact. For this 
reason, it will be necessary to study the combined actions of multiple 
receptor systems on behavioral sensitization, instead of assessing each 
system independently.  
 Although the dopamine, serotonin, and noradrenergic neurotransmitter 
systems may interact to mediate behavioral sensitization, it remains possible 
that other receptor types are also involved with this complex behavior. In 
terms of the present study, EEDQ may have blocked behavioral sensitization 
by affecting a receptor type that was not protected from alkylation. In addition 
to irreversibly antagonizing dopaminergic, serotonergic, and adrenergic 
receptors, EEDQ inhibits the release and high-affinity uptake of acetylcholine 
in the hippocampus (Vickroy & Malphurs, 1994). Therefore, besides 
examining the combined effects of monoamine neurotransmitter systems on 
behavioral sensitization, future experiments should also consider the roles 
played by other neural mechanisms.  
 In conclusion, EEDQ blocks the induction and expression of one-trial 
cocaine-induced behavioral sensitization. The protection experiments using 
ritanserin and prazosin indicate, but do not conclusively show, that the 
serotonergic and adrenergic receptor systems do not mediate the induction 
and expression of one-trial cocaine-induced behavioral sensitization in 
preweanling rats. Considering both past and present results, the most 
harmonious conclusion is that multiple receptor systems (i.e., dopaminergic, 
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serotonergic, adrenergic, etc.) work in unison to produce the complex 
phenomenon of behavioral sensitization.  
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